Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program

 Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program

Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program

Shots:

  • Gilead entered into a strategic collaboration with Glympse Bio to utilize Glympse’s technology, Glympse Inside in its NASH program to diagnose the stage of NASH as well as early detection of treatment response
  • The focus of the collaboration is to meet highly unmet medical needs and to improve the lives of patients by transforming the disease detection and measuring treatment response
  • Glympse Inside is a pan-disease product engine focusing on transforming disease monitoring and treatment response by integrating synthetic biomarkers with machine learning and AI

Click here to­ read full press release/ article | Ref: Gilead | Image: The Economic Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post